MD Anderson | Strategic Alliance Partners

Latest from MD Anderson


Frontline Encorafenib/Cetuximab Plus or Minus Chemo Is Under Evaluation for BRAF V600E–Mutant mCRC

May 25, 2022

The safety and efficacy of encorafenib plus cetuximab with or without standard-of-care chemotherapy will be compared with that of chemotherapy alone in patients with BRAF V600E–mutated metastatic colorectal cancer as part of the phase 3 BREAKWATER trial.

Immunotherapy Plus Nadofaragene Firadenovec Could Display Synergistic Activity in NMIBC

May 17, 2022

Nadofaragene firadenovec combined with immune checkpoint inhibitors such as pembrolizumab may play a synergistic role in the treatment of patients with Bacillus Calmette–Guérin-unresponsive non–muscle invasive bladder cancer.

Dr. Mitra on Nadofaragene Firadenovec Plus Anti–PD-1 Therapy in BCG-Unresponsive NMIBC

May 16, 2022

Anirban P. Mitra, MD, PhD, discusses data from an assessment of PD-1 and PD-L1 status on transurethral resection specimens collected from patients with non–muscle-invasive bladder cancer who received nadofaragene firadenovec as part of a phase 3 trial.

Sexual Harassment Rates Across Oncology Call for Improved Policies and Protections

May 12, 2022

Seventy percent of practicing oncologists had experienced sexual harassment by peers or superiors within 1 year, highlighting a substantial issue for both women and men, according to findings from a study that were published in the Journal of Clinical Oncology.

MD Anderson Receives Over $10 million from Break Through Cancer to Support Collaborative Research With Leading Cancer Centers

April 28, 2022

The University of Texas MD Anderson Cancer Center was awarded more than $10 million in grants to support collaborative research teams working to advance novel interception and treatment strategies that will improve outcomes for several cancer types with the greatest unmet need.

Nivolumab Plus Relatlimab Aims to Become Primary Treatment Option for Advanced Melanoma

April 21, 2022

The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve patients with unresectable or metastatic melanoma an efficacious and tolerable immunotherapy treatment option.

Research Efforts Seek to Further Explore the Potential of Uproleselan in AML

April 14, 2022

Tapan M. Kadia, MD, discusses what makes uproleselan unique from other agents under investigation in acute myeloid leukemia and sheds light on the many research efforts dedicated to further exploring its use in this disease.

Sotigalimab Plus Pembrolizumab Elicits Broad Immune Activity in Metastatic Melanoma

April 13, 2022

The combination of the CD40 agonist antibody sotigalimab and pembrolizumab demonstrated a favorable safety profile and led to immunologic changes that correlated with clinical response in patients with unresectable stage III or IV metastatic melanoma.